Still, regular lab monitoring (especially IGF-1 and fasting glucose levels) is essential to track efficacy and safety over time
Jupiter, Florida, Nov
GLP-1s are not going anywhere pharma manufacturers continue to evolve their GLP-1/GIP product offerings (e.g., Eli Lillys Zepbound is the newest on the market), and the number of addressable indications is increasing (e.g., recent clinical evidence that may merit further FDA approval of GLP-1s for cardio-metabolic, nephrological and neurological indications)
Associate Professor, Discipline of Surgery, Sydney Medical School, University of Sydney, NSW David Alexander Stewart MBChB, FRACS (Plast), Visiting Medical Officer, Department of Hand & Peripheral Nerve Surgery, Royal North Shore Hospital, St Leonards, NSW
Lancet (2013) 382(9894):81931
GLP-1s are in essence chemicals that the body produces in response to food